在Micra AV CED研究中,Micra AV无心脏起器的两年结果
Mikhael F El-Chami1, Lucas Higuera2, Colleen Longacre2
1Department of Medicine, Division of Cardiology, Emory University School of Medicine, 100 Woodruff Circle, 550 Peachtree Street NE, Atlanta, GA 30308, USA.
概括
与传统的双透静脉起器相比,Micra AV无起器在两年内显示出更少的并发症和重新干预. 然而,微型AV患者的全因死亡率仍然较高,可能是由于伴随性疾病的增加.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 健康 结果 研究 研究 结果
背景情况:
- 无节奏提供了一种安全的替代品,可以通过静脉节奏来治疗胸肌梗塞.
- 迈克拉AV是一款无心脏起器,提供心房同步心室节奏.
- 之前的研究表明,在医疗保险患者中,Micra AV可减少短期并发症.
研究的目的:
- 为了比较2年的慢性并发症,重新干预和全因死亡率.
- 评估Micra AV无心脏起器和传统的双室透静脉 (DC-TV) 心脏起器之间的结果.
- 评估无节奏技术的长期安全性和有效性.
主要方法:
- 使用的Medicare行政索赔数据与2020-2021年植入患者的设备注册相关.
- 包括7552名Micra AV患者和110,558名DC-TV心脏起器患者.
- 采用具有倾向分数的竞争风险模型重叠重量调整用于分析.
主要成果:
- 微型AV患者的共发病负担在基线较高.
- 2年后,Micra AV的复发率显著降低 (调整为5.3%对比9.6%) 和重新干预率 (调整为3.5%对比5.6%).
- 尽管并发症率较低,但Micra AV组的全因死亡率更高 (调整HR:1.53).
结论:
- 与DC-TV心脏起器相比,2年后,Micra AV无心脏起器与减少慢性并发症和重新干预有关.
- 在Micra AV患者中,全因死亡率更高可能归因于他们更大的并发症负担.
- 这项研究支持无步行器在程序和慢性并发症方面具有良好的安全性.
相关概念视频
01:22Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
01:25Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...